Non-Muscle Invasive Bladder Carcinoma — Trials

Non-Muscle Invasive Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 55
Recruiting: 35
Ph III recruiting: 8
Growth YoY: —
Industry share: 36%
Top sponsor: Janssen Research & Development, LLC
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03719300	Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC	terminated	Phase 2	32	Anchiano Therapeutics Israel Ltd.INDUSTRY	1	Aug 19, 2020	clinicaltrials
NCT03167151	Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla)	terminated	Phase 1 / Phase 2	6	University of OxfordOTHER	1	Jul 31, 2020	clinicaltrials